Myocardial infarction (MI) remains the leading cause of morbidity and mortality worldwide, and novel therapeutic targets still need to be investigated to alleviate myocardial injury and the ensuing maladaptive cardiac remodelling. Accumulating studies have indicated that lncRNA H19 might exert a crucial regulatory effect on cardiovascular disease. In this study, we aimed to explore the biological function and molecular mechanism of H19 in MI. To investigate the biological functions of H19, miRNA-22-3p and KDM3A, gain-and loss-of-function experiments were performed.
| INTRODUC TI ON
Coronary heart disease is characterized by the formation of stable atheromas that induce chronic myocardial ischaemia or of vulnerable plaques that lead to acute occlusive atherothrombotic complications. 1 Acute myocardial infarction (AMI), commonly known as heart attract, often occurs as the most serious and lethal manifestation of coronary heart disease. 2 The heart is extremely sensitive to ischaemic or hypoxic injury, and a rapid and persistent decrease in coronary artery flow secondary to coronary artery occlusion results in irreversible cardiomyocyte loss, leading to subsequent heart failure and even sudden cardiac death. 3 Despite significant progress in the treatment and management of the disease as well as improved secondary prevention measures, AMI remains the leading cause of disability and mortality worldwide. 2 Currently, the most effective strategy for the treatment of AMI mainly focuses on timely reperfusion of the ischaemic myocardium by dissolving the thrombus with medications or percutaneous coronary intervention. 4 Although these strategies are effective in limiting heart injury and reducing infarct size, patients with AMI remain at increased shortterm and long-term risk of heart failure, and only approximately half of patients survive for 5 years or longer after diagnosis. 5 Therefore, therapeutic approaches that could alleviate progressive maladaptive cardiac remodelling and improve heart performance in the long run are still the Holy Grail of this field.
The discovery of non-coding RNAs has provided a new perspective on gene regulation in multiple pathophysiological contexts. Among them, the biological functions of microRNAs have been extensively investigated in cardiovascular disease over the last decade. However, much less is known about the functional role of lncRNAs in this field. 6 LncRNAs are currently defined as transcripts that are longer than 200 nucleotides without evident protein-coding function. Thus far, lncRNAs have been perceived as involved in myriad biological processes and exert powerful regulating efficiency at the epigenetic, transcriptional and post-transcriptional levels. 7 As the homeostasis of the cardiovascular system requires the exquisite control of gene expression and transcriptional programs, it is reasonable to speculate that lncRNAs might emerge as crucial mediators in cardiovascular diseases.
LncRNA H19 is located near the telomeric region of human chromosome 11 in the H19 gene, which is one of the most wellknown imprinted genes. 8 H19 is abundantly expressed in embryonic tissues of endodermal and mesodermal origin, and it has been demonstrated to be expressed mainly in skeletal muscle and the heart in adults. 9 H19 has been deemed to be involved in heart development and blood vessel formation. 10 In addition, several prospective experiments have also indicated that H19 plays a vital role in cardiovascular diseases, such as myocardial ischaemia-reperfusion injury, cardiac hypertrophy and aortic calcification. [11] [12] [13] Moreover, aberrant expression of H19 has been identified in AMI patients in clinical studies. 14 However, whether H19 participates in the pathological progress of AMI and its potential function remain largely obscure.
Lysine (K)-specific demethylase 3A (KDM3A), also named Jumonji domain-containing 1A (JMID1A), is an important epigenetic mark that exerts its biological effects by specifically demethylating mono-methyl and di-methyl histone H3K9 (H3K9me1/2) and consequently modulating target gene expression. 15 As H3K9 methylation in promoter regions is usually regarded as a suppressive histone mark that inhibits transcription, the role of demethylase KDM3A tends to be as an epigenetic activator that facilitates gene transcription. Numerous studies have elucidated the pathophysiological significance of KDM3A in various tumours as a poor prognostic indicator 16 ; however, its potential function in cardiovascular disease is still enigmatic. Our previous studies have provided firm evidence that KDM3A is implicated in diabetic vascular remodelling and diabetic cardiomyopathy as well as myocardial ischaemia-reperfusion injury by regulating key signalling pathways that are involved in inflammation, apoptosis and oxidative stress. 15, 17 In addition, Zhang and colleagues also reported that KDM3A participated in left ventricular hypertrophy and myocardial fibrosis in response to pressure overload. 18 In the light of these considerations, we speculated that KDM3A may play a central role in the regulatory network of AMI.
The present study was designed to determine whether lncRNA H19 was involved in the pathophysiological process of AMI as well as to explore the underlying molecular biological mechanisms. Using an in vivo rat AMI model, our experiment provides compelling evidence that H19 could modulate the expression of KDM3A by competitively binding to miR-22-3p, which consequently ameliorated AMI-induced myocardial damage and cardiac remoulding.
| MATERIAL S AND ME THODS

| Reagents
Dulbecco's modified Eagle's medium (DMEM/F12), foetal bovine serum (FBS) and collagenase II were obtained from HyClone. Trypsin was provided by Beyotime. All other cell culture reagents were purchased from Sigma Chemicals unless otherwise specified. Primary antibodies against KDM3A, ETS-1, Bax, Bcl-2, IL-6, TNF-α, GAPDH, ANP and BNP were purchased from Abcam. The secondary antibodies, either HRP-linked goat anti-mouse IgG or goat anti-rabbit IgG, were also obtained from Abcam. The miR-22-3p mimic and its scrambled oligonucleotides (miRNA-NC) were synthesized by GenePharma Co., Ltd. 
| Animals
| KDM3A knockout rats
The KDM3A gene knockout rat (SD background) was conducted by using CRISPR/Cas9 genome-editing technology. In brief, one single-guide RNA (sgRNA) flanking exon 5 of the KDM3A gene in rats was designed. Then, purified Cas9 mRNA and the sgRNA were mixed and microinjected into embryos. PCR products were TA cloned and sequenced to define the exact insertion/deletion mutations of the generated founder rats. The founder rats with multiple mutated alleles were identified and mated with the wild-type SD rat (KDM3A+/+) strain to generate F1 heterozygotes (KDM3A+/−).
Thereafter, KDM3A gene deletion homozygote rats (KDM3A−/−) were obtained through sibling mating of the heterozygous F1 generation. The KDM3A-KO rats were identified and screened by sequencing of PCR products. Western blot assays were performed to verify KDM3A protein expression as well.
| Adenoviral constructions and transfection
The following were inserted into adenoviral vectors according to the manufacturer's instructions (GeneChem): the full-length rat lncRNA H19 sequence (Ad-H19) to ensure H19 expression, a short-hairpin RNA (Ad-shH19) directed against lncRNA H19 and the associated negative control oligonucleotides. Recombinant adenoviruses for miR-22-3p overexpression (Ad-miR-22) and miR-22-3p silencing (Ad-Antagomir-22), as well as their negative control, were also constructed by GeneChem. The adenovirus encoding KDM3A (Ad-KDM3A), which has been verified to be efficient in inducing the overexpression of KDM3A in vivo, 15 was provided by GeneChem as well, and Ad-GFP was used as a control.
Five days before the establishment of the AMI model, rats were anaesthetized, and the pericardium was removed through a small left anterior thoracotomy. Then, 100 µL of adenovirus solution was intramyocardially injected into five separate sites of the left ventricle by using a microsyringe. Five days later, the rats that survived were subjected to AMI surgery.
| Establishment of the rat AMI model
The rat AMI model was established as previously described. 19 Briefly, animals were anaesthetized with intraperitoneally injected pentobarbital sodium (60 mg/kg). Then, a volume-controlled small animal respirator was used to support the breathing of the rats through a tracheal cannula, and a standard electrocardiogram was used to continuously monitor the heart rate. Subsequently, a left thoracotomy was performed to expose the heart, and a 6-0 silk suture on a small curved needle was passed through the myocardium beneath the left arterial descending (LAD) branch of the coronary artery. The LAD was ligatured to induce myocardial ischaemia. A successful AMI model was confirmed by an elevated ST segment in leads-II and a regional paleness of the myocardial surface. Rats in the sham-operated group were subjected to the same procedure except the snare was left untied. Four weeks after surgery, the rats were killed, and the hearts were harvested for further analysis.
| Isolation and culture of primary cardiomyocytes
Primary neonatal cardiomyocytes were isolated from the heart of 1-3-day-old rats and cultured in DMEM/F12 containing 15%
FBS. In brief, hearts were rapidly removed from anaesthetized infant rats, and the ventricular myocardium was dissected into small pieces under sterile conditions. After digestion with 0.125% trypsin for 10 minutes, the myocardial tissue was collected and continued to be digested with a mixed enzyme solution containing 0.125% trypsin and 0.08% collagenase II at 37°C until there was no obvious tissue left. The digested cells in the supernatant were collected and centrifuged at 1000 rpm for 10 minutes and then pre-plated into cell culture dishes for 90 minutes to separate cardiomyocytes from cardiac fibroblasts by adherence. At the end of the differential adhesion process, the non-attached cardiomyocytes that were suspended in DMEM were collected and reseeded into cell culture dishes with medium containing 15% FBS and 1% penicillin/streptomycin for 72 hours before any subsequent treatment.
| Assessment of heart morphology and cardiac function
Four weeks after MI surgery, rat hearts of each group were extirpated and transected at the plane of the papillary muscle, followed by freezing in an OCT compound. Sections of 10 μm thickness were obtained every 100 μm, and Masson's trichrome staining was performed according to the manufacturer's instructions. Thereafter, images were acquired using a Pannoramic MIDI Slide Scanner. The percentage of infarcted areas in each section was calculated.
Transthoracic echocardiography was performed on rats lightly anaesthetized by inhaling isoflurane. Left ventricular function at the end of the experiment was measured by using the MyLab 30CV ultrasound system (BiosoundEasote, Inc). Two-dimensional guided M-mode tracings were recorded in short-axis views at the level of mid-papillary muscles. Then, the left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) were measured. All measurements were made from at least three representative cycles and averaged.
| Evaluation of myocardial apoptosis and fibrosis
After the animals were killed, myocardial samples of each group were fixed in 4% paraformaldehyde and embedded in paraffin. The apoptosis of cardiomyocytes was measured by TUNEL staining according to the manufacturer's instructions (Roche Applied Science). Anti-α-actinin antibody was used to identify the cardiomyocytes, while red fluorescent dye and DAPI were used to label the apoptotic nuclei and normal nuclei, respectively. At least five randomly selected fields per section were observed under a fluorescence microscope (400× magnification). The apoptosis index (AI) was calculated as the ratio of TUNEL-positive cells (red) to total cardiomyocytes (blue). Myocardial remodelling after infarction was determined by Masson's staining as previously described. 19 Areas stained in blue indicate the deposition of collagen fibrils. All histological assessments were performed by an investigator who was blinded to the experiment.
| Luciferase reporter assay
Bioinformatics analysis predicted that H19 contains canonical bind- was used to examine the luciferase activity in each group.
| RNA immunoprecipitation (RIP) assay
A RIP assay was performed using a Magna RIP™ RNA-Binding Protein
Immunoprecipitation Kit (Millipore) following the manufacturer's instructions as described in a previous study. 20 Cardiomyocytes were lysed in RNA lysis buffer containing protease and RNase inhibitors.
Then, a portion of the cell extract was isolated as the input, while the other portion was incubated with an antibody for coprecipitation by incubation with RIP immunoprecipitation buffer containing magnetic beads conjugated with anti-Argonaute protein 2 (Ago-2) antibody (Millipore) or control anti-IgG antibody (Millipore) as a negative control. The samples were then incubated with proteinase K to digest the unbound proteins, and immunoprecipitated RNA was isolated. Subsequently, qRT-PCR assays were conducted to determine H19 and miR-22-3p levels in the precipitates.
| Pull-down assay with biotinylated miR-22-3p
Cardiomyocytes were transfected with biotinylated miR-22-3p-WT or biotinylated miR-22-3p-Mut. After incubation for 48 hours, cells were collected and lysed with lysis buffer. Cells lysates were then incubated with streptavidin-coated magnetic beads (M-280
Dynabeads; Invitrogen). To prevent non-specific binding of RNA and protein complexes, the beads were also coated with RNase-free bovine serum albumin (BSA) and yeast tRNA (Sigma). After incubation at 4°C for 3 hours, the beads were rinsed with ice-cold lysis buffer and washed three times with low-salt buffer and once with high-salt buffer. The bound RNAs were purified using TRIzol, and the level of H19 was analysed.
| Pull-down assay with biotinylated H19
To identify whether H19 could pull down miR-22-3p, the cardiomyocytes were also transfected with biotin-labelled Bio-probe NC, BioLncRNA H19-WT and Bio-LncRNA H19-Mut. 48 hours later, the cells were lysed and incubation with M-280 streptavidin magnetic beads as described above. Afterwards, the beads were washed with precooled lysis buffer, low-salt buffer and high-salt buffer in sequence.
Subsequently, the RNA complexes bound to the beads were purified by TRIzol, the level of miR-22-3p was tested by RT-PCR.
| Quantitative RT-PCR and Western blot analyses
Quantitative RT-PCR (qRT-PCR) was performed as previously described. 19 The For the Western blot assay, myocardial samples were lysed and proteins were extracted according to the specification of manufacturers. Total proteins were separated by 10% SDS-PAGE and electrophoretically transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore). Then, 5% non-fat dried milk was used to block non-specific binding to the membranes, and the membranes were incubated with primary antibodies overnight, followed by incubation with the corresponding secondary antibodies. The protein bands were visualized using an enhanced chemiluminescence system (Thermos Fisher Scientific, Inc). GAPDH was used as an internal loading control.
| Statistical analysis
Continuous values were presented as mean ± standard deviation (SD). Student's t-test was used for comparisons between two groups.
One-way analysis of variance (ANOVA) was used for comparisons among multiple groups, and Student-Newman-Keuls (SNK)-q tests were used for subsequent analysis between multiple comparisons.
P-value of <.05 was considered statistically significant. All statistical analyses were performed using SPSS 19.0 software.
| RE SULTS
| LncRNA H19 overexpression attenuated while lncRNA H19 inhibition exacerbated myocardial injury caused by MI
To determine whether H19 is involved in the pathological process of MI, we first assessed H19 levels in myocardial tissue 4 weeks after MI. As shown in Figure 1A , H19 expression was much lower in the myocardium of the infarcted border zone when compared with that in the normal left ventricle. To further explore the impact of H19 on MI, we performed controlled gain-and loss-of-function experiments to identify the effects of H19 in vivo. Five days before the MI surgery, rats were intramyocardially injected with either Ad-H19
or Ad-shH19 to stably up-regulate or down-regulate H19 levels, respectively ( Figure 1B,C) . At the end of the experiments, morphology and cardiac function as well as related molecular biological alterations in each group were rigorously scrutinized.
As shown in Figure 1D , transfection with Ad-H19 significantly increased H19 levels after MI (P < .05). In addition, Masson's trichrome staining at the papillary muscle plane suggested an obvious reduction in infract size in Ad-H19-infected MI rats Moreover, H19 overexpression also prominently down-regulated the level of the pro-apoptosis protein Bax while it up-regulated the level of the anti-apoptotic protein Bcl-2 ( Figure 1K ; P < .05).
However, the outcome was distinctly reversed when the heart was infected with Ad-shH19 to knock down H19 expression. As shown in Figure 2B ,C,D and E, H19 inhibition further enlarged the infract size, deteriorated the compromised cardiac function and aggravated the degree of myocardial fibrosis (P < .05).
Moreover, H19 knockout dramatically exacerbated inflammation and myocardial apoptosis, as evidenced by enhanced levels of inflammation and apoptosis-associated parameters ( Figure 2F ,G and H; P < .05). Therefore, the above gain-and loss-of-function experiments strongly suggest that H19 may act as a therapeutic target of MI.
| LncRNA H19 could directly interact with miR-22-3p and regulate its expression
Ample evidence suggests that lncRNAs in the cytoplasm may exert their biological activities by acting as competing endogenous RNAs to decoy or adsorb miRNAs. To conduct a thorough inquiry on how H19 participates in the regulation of MI, we first used bioinformatics software (RAID V2.0 and Starbase) to screen potential candidate miRNAs that could bind to H19, and miR-22-3p was identified. In addition to containing a putative H19 binding site, previous studies have demonstrated that miR-22-3p plays a key role in cardiovascular disease, and our data indicated that its level was notably up-regulated after MI ( Figure 3A ; P < .05). Importantly, as presented in Figure 3A ,B, there was a negative correlation between H19 and miR-22-3p after MI, namely, enforcing H19 expression significantly Figure 3H , the data indicated that H19 was pulled down Collectively, the data above suggest that H19 could directly interact with miR-22-3p in rat cardiomyocytes.
| miR-22-3p knockdown ameliorated myocardial injury caused by MI
To better understand the potential biological function of miR- 22-3p in the heart, we constructed recombinant adenoviruses containing Antagomir-22 (Ad-Antagomir-22) to knock down the expression of miR-22-3p. As shown in Figure 4A , the RNA level of miR-22-3p was distinctly down-regulated after transfection with Ad-Antagomir-22 F I G U R E 3 miRNA-22-3p is a direct target of H19 in cardiomyocytes. A, The miRNA-22-3p levels were measured by qRT-PCR after up-regulation of H19 expression by adenovirus infection. *P < .05 versus the SO group; **P < .05 versus the MI + Ad-NC group. B, Levels of miRNA-22-3p after down-regulation of H19 expression by adenovirus infection. *P < .05 versus the SO group; **P < . Concomitantly, the inflammatory response was abated, and the cardiomyocyte apoptosis index was reduced in response to miR-
22-3p knockdown after MI, as evidenced by the changes in inflammation-related indicators (IL-6, TNF-α) and apoptosis markers (Bax,
Bcl-2) ( Figure 4F , G, and H; P < .05). To confirm whether KDM3A is a bona fide target of miR-22-3p, a luciferase reporter assay was performed. HEK293T cells were cotransfected with pmirGLO-KDM3A-WT or pmirGLO-KDM3A-Mut and miR-22-3p mimics or miRNA-NC. As shown in Figure 5F , miR-22-3p mimics dramatically reduced the luciferase activity of the pmirGLO-KDM3A-WT group compared with the miRNA-NC group (P < .05).
| KDM3A is a direct target of miR-22-3p, and its
However, neither the miR-22-3p mimic nor its negative control evidently influenced luciferase activity in the pmirGLO-KDM3A-Mut group (P > .05).
| KDM3A overexpression alleviated while KDM3A knockout deteriorated myocardial injury induced by MI
To investigate whether KDM3A is involved in MI, another set of controlled gain-and loss-of-function experiments was performed.
Rat hearts were transfected with adenovirus encoding KDM3A (Ad-KDM3A) to up-regulate the level of KDM3A ( Figure 6A ; P < .05).
KDM3A-KO rats were used to down-regulate the expression of KDM3A ( Figure 7A ; P < .05). As presented in Figure 6B ,C and 6, 
| D ISCUSS I ON
Although extensively applied reperfusion therapy has greatly improved patient outcome, AMI is still correlated with high mortality, and the overall clinical prognosis remains unsatisfactory. 21 In addition to acute myocardial ischaemic damage and reperfusion injury, heart failure triggered by the ensuing maladaptive ventricular remodelling can be a truly difficult issue to tackle. 22 Although only a very small percentage of lncRNAs have been identified and investigated experimentally so far, it has been well confirmed that lncRNAs are implicated in multiple complex biological processes. 6, 23, 24 LncRNAs are so versatile that they have been proposed to possess the capability to interact with protein, DNA and various kinds of RNAs to elicit gene activation or inhibition effects. 25 Recently, accumulating evidence has been presented in the literature, providing verification of the pivotal roles played by lncRNAs in the homeostasis of the cardiovascular system. Aberrant expression of LncRNAs such as Fendrr, Bvhta and KCNQ1OT1 may lead to congenital cardiovascular diseases and malformations. 10 Besides, ANRIL, MIAT and MALAT1 have been demonstrated to play crucial roles in ischaemic heart disease. 26 In addition, enforced expression of Mhrt ameliorated cardiac hypertrophy, 27 while CHRF up-regulation exacerbated cardiomyocyte hypertrophy. 28 Moreover, lncRNAs might serve as new biomarkers of heart diseases. Mitochondrial lncRNA LIPCAR was identified as a biomarker of ventricular remodelling after MI and a predictor of death in patients with heart failure, which confirms the principle that plasma lncRNAs might be used as biomarkers of prognosis in cardiovascular diseases. 29 LncRNA H19 was the first imprinted lncRNA identified. In contrast to many other lncRNAs that are prone to variation, H19 possessing a highly evolutionarily conserved secondary structure and a sequence consistent among multiple species with only a few mutations in exon regions. 9, 12 As the vast disparities of its expression level in the cardiovascular system before and after birth as well as under normal and pathological conditions, H19 has recently drawn considerable interest among researchers investigating cardiovascular disease. 12, 14 In the pathological process of myocardial ischaemia-reperfusion in- promoter was associated with the abnormal mineralization of the aortic valve by silencing the NOTCH1 pathway. 13 In addition to being an independent lncRNA, H19 also carries a miRNA-containing hairpin, which could serve as a template to encode miR-675 and inhibit Interestingly, investigators have verified that H19 is a key mediator involved in myocardial inflammatory reactions and apoptosis. 12, 30, 31 Consistent with these previous studies, the data from our study clearly illustrated that H19 up-regulation not only significantly If we are only at the beginning of understanding the role of H19
in AMI, we are even further away from comprehending the underlying mechanism. The competing endogenous RNA (ceRNA) theory has shed new light on how H19 participates in the pathological process of AMI. 32 There is wide consensus that lncRNAs may exert their biological effects by acting as endogenous decoys to sponge miRNAs, which consequently segregates miRNAs from their target mRNAs. 20, 25 In recent decades, the vital function of miRNAs in cardiovascular disease has been well characterized. Among them is miRNA-22-3p, which was shown to be enriched in strained muscle tissues and has been confirmed to be involved in various cardiovascular disorders through regulating inflammation, apoptosis, oxidative stress and autophagy. [33] [34] [35] [36] In our present study, we transfected cardiomyocytes with adenovirus containing siRNA to down-regulate the miRNA-22-3p level to explore its effect on AMI. As expected, miRNA-22-3p knockdown significantly decreased the MI-post infarction area and improved cardiac function as well as alleviated myocardial fibrosis. Moreover, the inflammatory response and apoptosis were also mitigated. Therefore, miRNA-22-3p inhibition could ameliorate myocardial injury. An interesting phenomenon is that in contrast to the expression status of H19 in the heart, the level of cardiac miR-22-3p is much higher in mature cardiomyocytes when compared with those of embryonic and neonatal hearts. 33 Our data revealed a negative correlation between H19 and miRNA-22-3p levels in AMI, and bioinformatics analysis also showed that H19 contains a putative binding site for miRNA-22-3p. In addition, previous studies performed by Wang activity concomitant with reduced inflammation, ROS and apoptosis.
As both inflammation and apoptosis are critical underlying mechanisms of AMI and cardiac remoulding, we speculate that KDM3A might be involved in the pathological process of AMI by regulating the expression of ETS-1. A previous study published by Parrish and col- leagues uncovered that KDM3A is a miRNA-22-3p-regulated tumour promoter in Ewing sarcoma. 42 Here, our data not only demonstrated a negative correlation between miRNA-22-3p and KDM3A in MI, but the subsequent luciferase reporter assay also confirmed that miR-NA-22-3p could directly combine with KDM3A mRNA. Therefore, the data above indicated that miRNA-22-3p might participate in AMI through regulating the expression of KDM3A. Intriguingly, we found that H19 shares the same miR-22-3p binding sites with the KDM3A mRNA 3'-UTR. To verify that miRNA-22-3p is a specific mediator between H19 and KDM3A, we then performed a rescue experiment to up-regulate the expression of H19 and miRNA-22-3p in myocardium at the same time. The result from this study indicated that enforced miRNA-22-3p expression could partly counteract the beneficial cardiac protective effect of H19 overexpression and reverse the protein levels of KDM3A and ETS-1. Based on the above results, we concluded that H19 could sponge miRNA-22-3p to ameliorate AMIinduced myocardial damage by up-regulating KDM3A.
| CON CLUS ION
In summary, we identified that lncRNA H19 expression was signifi- (Table 1 ).
In addition, it has also been reported that some transcription factors such as TGF-β and DNA methyltransferase such as DNMT-1 might serve as the upstream regulator of H19 and participate in the pathological process of other diseases. As a result, further studies are still needed to establish if there are other direct links between H19 and other signalling pathways that participate in the pathological process of AMI.
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